WAT Waters Corporation

Waters Extends the Capability and Power of its High-Resolution Mass Spectrometers

Waters Corporation (NYSE:WAT) announced today a new fragmentation technique and an imaging option for its high-resolution mass spectrometers giving research scientists working across a broad range of end markets including biomedical, biopharmaceutical and food research, greater experimental freedom to explore the intricacies of peptides, proteins, and protein complexes.

This press release features multimedia. View the full release here:

The Waters Desorption Electrospray Ionization (DESI) imaging option (DESI XS) for Waters’ high-resolution mass spectrometers, opens up new paths of discovery for scientists investigating small molecule drug compounds for treating human disease (Photo: Business Wire)

The Waters Desorption Electrospray Ionization (DESI) imaging option (DESI XS) for Waters’ high-resolution mass spectrometers, opens up new paths of discovery for scientists investigating small molecule drug compounds for treating human disease (Photo: Business Wire)

“This is a time for science to step up and show what it can do for humanity,” said James Langridge, PhD, Senior Director, Advanced Mass Spectrometry, Waters Corporation. “Understanding the biology of disease and discovering new treatments requires us to continue innovating new and powerful capabilities for mass spectrometry so that scientists can accurately and confidently answer their scientific questions.”

New Fragmentation Option for Waters Cyclic IMS System

For its high-performance System, Waters will offer scientists the ability to probe the structure of proteins, peptides, glycans and other biomolecules with Electron Capture Dissociation (ECD), a fragmentation technique made available through a partnership with e-MSion, Inc. (Portland, Oregon).

ECD is an electron-based fragmentation technology that, combined with ion mobility mass spectrometry and Collision Induced Dissociation (CID) available with the Cyclic IMS System, gives scientists improved sequence coverage for native proteins and surrogate peptides and additional structural information about larger proteins that might not have been possible before.

The versatile Waters™ Cyclic IMS System is the only ion mobility time-of-flight mass spectrometer to perform scalable ion mobility separations and that is also capable of IMSn experiments (e.g. selecting an ion by IMS, fragmenting the ion, selecting a particular fragment by IMS and repeating the process) which derives detailed structural information about a single analyte.

“I am very impressed by the performance of the Waters Cyclic IMS system for resolving isomeric post-translationally modified peptides and their subsequent structural analysis by ECD MS/MS,” said Prof. Ole Nørregaard Jensen, Director, at the . “The combination of cIMS and ECD MS/MS provides new opportunities for detailed structural characterization of modified peptides and large protein domains in biology, biomedicine and pharmacology.”

DESI XS Imaging Now Available on Waters SELECT SERIES Cyclic IMS, SYNAPT XS and Xevo G2-XS Time-of-Flight Mass Spectrometers

For the first time, the new source is available on the Waters SELECT SERIES Cyclic IMS, , and Mass Spectrometers. Waters acquired the rights to DESI™ IP from Prosolia, Inc. and the Purdue Research Foundation in 2018, making Waters the exclusive provider of this technology. The new Waters DESI XS source retains the performance of the original version and features enhanced reliability and user experience, making high quality MS imaging accessible to a broader range of scientists.

When coupled to a mass spectrometer, DESI XS produces a visual map of the spatial distribution of small molecule drugs, metabolites and lipids within a variety of sample and surface types. With DESI XS, scientists can image tissue samples, screen metabolites in bacterial colonies, identify individuals from fingerprints taken directly from various surfaces and examine cross-sections of natural products like roots and tubers.

As a direct ionization source, DESI XS eliminates the need for sample preparation and chromatography prior to the introduction of the sample into the mass spectrometer, saving scientists time, lab space and expense.

MassLynx Mass Spectrometry Software Now Interfaces with Skyline Software

For customers with and mass spectrometers running on version 4.2, Waters is introducing a new interface to , the freely-available, open source software for targeted proteomics. The interface will enable scientists to develop optimized LC-MS/MS multiple reaction monitoring (MRM) methods for the quantification of peptides or protein digests by the surrogate peptide approach. The is an easy-to-use tool for auto-optimizing and fine-tuning high-sensitivity MRM assays on tandem quadrupole mass spectrometers for bioanalytical or targeted proteomics experiments that are part of drug discovery research.

Product Availability

The ECD and DESI XS options for the SELECT SERIES Cyclic IMS System will ship in the fourth quarter of this year. Existing Waters Cyclic IMS customers will also be able to add these new options to their instruments at the same time. DESI XS is now available to ship with new Xevo G2-XS QTof and SYNAPT XS Systems. It is also available as an upgrade option for previously installed Xevo G2-XS QTof and SYNAPT XS systems.

The Waters MassLynx/Skyline interface is available now and can be downloaded for free from the .

Additional Resources:

  • Read the Waters Blog: “”
  • Learn more about
  • Learn more about
  • Download
  • Connect with Waters via , , and

About Waters Corporation ()

(NYSE:WAT), the world's leading specialty measurement company, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,000 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

Waters, Cyclic, SELECT SERIES, Xevo, SYNAPT, DESI and MassLynx are trademarks of Waters Corporation.

EN
23/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Waters Corporation

Waters Corp: 1 director

A director at Waters Corp bought 1,000 shares at 332.900USD and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

 PRESS RELEASE

Waters Launches its Most Sensitive and Compact Clinical IVD System wit...

MONTEREY, Calif.--(BUSINESS WIRE)-- MSACL Conference 2023--Waters Corporation (NYSE:WAT) today unveiled its next generation Xevo TQ Absolute IVD mass spectrometer, expanding its family of for clinical diagnostic applications. This press release features multimedia. View the full release here: Waters' newest MassTrak IVD LC-MS/MS System featuring the Xevo TQ Absolute IVD tandem quadrupole mass spectrometer (in dark grey), is up to five times more sensitive than similar commercial mass spectrometers for quantifying analytes in samples of saliva, breath, and dried blood spots. (Photo: Business...

 PRESS RELEASE

Waters Corporation Appoints Richard Fearon to Board of Directors

MILFORD, Mass.--(BUSINESS WIRE)-- Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. “Rick’s expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters’ growth plan. We are confident that Rick’s unique skillset will complement our Board well and we look forward to benefiting from his insights a...

 PRESS RELEASE

Waters lance le système de CLHP Alliance iS de nouvelle génération, qu...

PHILADELPHIE--(BUSINESS WIRE)-- PITTCON 2023 – Waters Corporation (NYSE:WAT) a lancé aujourd'hui , le système intelligent de CLHP de nouvelle génération, conçu pour réduire le risque de conformité en ajoutant de nouveaux niveaux de détection proactive des erreurs, de résolution des problèmes et une facilité d’utilisation. Lorsqu’il est associé au conforme et à de Waters, le système de chromatographie liquide à haute performance (CLHP) Alliance iS permet de rationaliser la tâche consistant à faire des mesures exactes et précises en détectant et éliminant les erreurs courantes jusqu’à 40 %.i C...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch